AEterna Zentaris (TSX:AEZS) EV-to-Revenue : -5.46 (As of Apr. 30, 2024)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, AEterna Zentaris's enterprise value is C$-33.11 Mil. AEterna Zentaris's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was C$6.06 Mil. Therefore, AEterna Zentaris's EV-to-Revenue for today is -5.46.

The historical rank and industry rank for AEterna Zentaris's EV-to-Revenue or its related term are showing as below:

TSX:AEZS' s EV-to-Revenue Range Over the Past 10 Years
Min: -463.11 Med: 0.89 Max: 2763.28
Current: -5.47

During the past 13 years, the highest EV-to-Revenue of AEterna Zentaris was 2763.28. The lowest was -463.11. And the median was 0.89.

TSX:AEZS's EV-to-Revenue is ranked better than
95.74% of 1034 companies
in the Biotechnology industry
Industry Median: 7.69 vs TSX:AEZS: -5.47

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-30), AEterna Zentaris's stock price is C$2.67. AEterna Zentaris's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$1.25. Therefore, AEterna Zentaris's PS Ratio for today is 2.14.

AEterna Zentaris EV-to-Revenue Historical Data

The historical data trend for AEterna Zentaris's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris EV-to-Revenue Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

20.91

0.64

-4.18

-6.22

-5.43

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-6.22	-5.55	-3.36	-3.86	-5.43

Competitive Comparison of AEterna Zentaris's EV-to-Revenue

For the Biotechnology subindustry, AEterna Zentaris's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's EV-to-Revenue falls into.

AEterna Zentaris EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

AEterna Zentaris's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	-33.111	/	6.062
	=	-5.46

AEterna Zentaris's current Enterprise Value is C$-33.11 Mil.
AEterna Zentaris's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$6.06 Mil.

AEterna Zentaris (TSX:AEZS) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

AEterna Zentaris's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	2.67	/	1.248
	=	2.14

AEterna Zentaris's share price for today is C$2.67.
AEterna Zentaris's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.25.

AEterna Zentaris EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.